ANG-2 NanoAb - Scinai Immunotherapeutics
Alternative Names: anti-ANG-2 NanoAb - Scinai ImmunotherapeuticsLatest Information Update: 25 Oct 2023
At a glance
- Originator Scinai Immunotherapeutics
- Class Antibodies; Eye disorder therapies
- Mechanism of Action Angiopoietin-2 modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Wet age-related macular degeneration
Most Recent Events
- 12 Sep 2023 Early research in Wet age-related macular degeneration in Israel (Scinai Immunotherapeutics pipeline, September 2023)